Stocks Set To Post Fresh All Time High As Tech Euphoria Returns
Stocks Set To Post Fresh All Time High As Tech Euphoria Returns
Futures are fractionally higher, as they have been much of this supercharged week which pushed stocks to new all tim ehighs,?amid quiet news flow this morning. As of 8:00am ET, S&P futures are up 0.1%?after the index...
Zero Hedge
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates
ARS Pharmaceuticals, Inc. (SPRY) delivered earnings and revenue surprises of -14.55% and +5.54%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
SPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026
SPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026 SPRY Deadline Alert: SueWallSt Reminds ARS Pharmaceuticals Inc. (SPRY) Investors of Securities Class Action Deadline on October 5, 2026 PR Newswire NEW YORK, Aug...
PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action...
PR Newswire
SPRY UPCOMING DEADLINE: Levi & Korsinsky Alerts ARS Pharmaceuticals Inc. Stockholders of Securities Class Action - Contact the Firm
SPRY UPCOMING DEADLINE: Levi & Korsinsky Alerts ARS Pharmaceuticals Inc. Stockholders of Securities Class Action - Contact the Firm SPRY UPCOMING DEADLINE: Levi & Korsinsky Alerts ARS Pharmaceuticals Inc. Stockholders of Securities Class Action - Contact the Firm PR Newswire NEW YORK, Aug. 12, 2026...
PR Newswire
SPRY Investors with Losses in Excess of $100K Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
SPRY Investors with Losses in Excess of $100K Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit SPRY Investors with Losses in Excess of $100K Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK, Aug. 11, 2026 NEW YORK, Aug. 11...
PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm PR Newswire NEW YORK, Aug. 11, 2026 NEW YORK...
PR Newswire
SPRY DEADLINE: The Gross Law Firm Reminds ARS Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline
SPRY DEADLINE: The Gross Law Firm Reminds ARS Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline SPRY DEADLINE: The Gross Law Firm Reminds ARS Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline PR Newswire NEW YORK, Aug. 11, 2026 NEW YORK, Aug...
PR Newswire
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY PR Newswire LOS ANGELES, Aug. 10, 2026 LOS ANGELES, Aug. 10...
PR Newswire
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (ARS or the Company) (NASDAQ: SPRY) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated...
Business Wire